Brian Daniels

418 posts

Brian Daniels banner
Brian Daniels

Brian Daniels

@SpicyBrian

Bioengineer, genome editor, drug developer. My comments are my own; my retweets are other people's. Your word is who you are.

Boston, MA Katılım Nisan 2009
466 Takip Edilen250 Takipçiler
Jing Liang 🇺🇦
Jing Liang 🇺🇦@AppleHelix·
The number of negative EV companies down >75% in past year is staggering. Some of these can probably 10x or more with the right assets and execution
Jing Liang 🇺🇦 tweet media
English
14
7
79
25.4K
Brian Daniels retweetledi
Flagship Pioneering
Flagship Pioneering@FlagshipPioneer·
#FlagshipFounded @TesseraTx announces an agreement with the @gatesfoundation to jointly fund development of globally accessible in vivo genetic therapies for sickle cell disease.
Tessera Therapeutics@TesseraTx

Today, we announced we have entered into an agreement with the @gatesfoundation to jointly fund our in vivo program for sickle cell disease (SCD). Read more here: tesseratherapeutics.com/news/tessera-t…

English
0
2
9
1.4K
Brian Daniels
Brian Daniels@SpicyBrian·
@RNAiAnalyst Didn't they already sell their Casgevy economics to DRI Healthcare Trust?
English
0
0
2
535
Dirk Haussecker
Dirk Haussecker@RNAiAnalyst·
$EDIT $250M in cash, $120M market cap. What is the point of re-booting the Co? Most shareholder friendly option would have been to not just fire 65%, but 100%, i.e. close down the Co + sell itself and Cas9 royalty potential ( $VRTX/ $CRSP, $NTLA, and possibly Cas9-related base editing royalty stream from $BEAM) to $RPRX or the likes.
English
8
2
52
13.5K
Yair Einhorn
Yair Einhorn@yaireinhorn·
1/@blueallele - a BioTech company focused on advancing transformational gene editing technologies, filed a patent infringement lawsuit against @intelliatx in the District Court of Delaware for the alleged infringement of its bi-directional insertion template patents. $NTLA $XBI
Yair Einhorn tweet media
English
4
5
19
3.7K
BowTiedBiotech 🧪🔬🧬
BowTiedBiotech 🧪🔬🧬@BowTiedBiotech·
2024 BIOTECH FIERCE 15: 1. Abdera: Radiopharma 2.Ascidian: RNA editing 3.BigHat: AI / Antibodies 4.Cour: Immune Tolerance 5.Excision: CRISPR anti-viral 6.Fauna: Novel Targets Platform 7.Gilgamesh: Psychedelics 8.iECURE: Gene Insertion 9.ILiAD: Vaccines 10.Kimer Med: Anti-virals 11.NodThera: Inflammasome 12.OMass: Mass spec novel target id 13.ProFound: Translatome 14.Recludix: Targeting SH2 domains 15.Tubulis: Novel ADCs fiercebiotech.com/special-report…
English
5
8
30
5.2K
Wei Zhao
Wei Zhao@zhaoweiasu·
Congrats to you two on your new positions! In the future, I hope you value the trust HMS placed in you and strive to be more transparent about the limitations of your research, such as your Cas13 RNA editing work (REPAIR/RESCUE), as revealed here.(ncbi.nlm.nih.gov/pmc/articles/P…) "Most of the experiments reported by Cox DBT, Gootenberg JS, Abudayyeh OO, are done under such co-overexpression conditions and it remains unclear to which extent those results rely on a true (Cas-dependent) targeting mechanism and which are overexpression artefacts (self targeting)."
English
1
3
5
3K
Omar Abudayyeh
Omar Abudayyeh@omarabudayyeh·
Please RT! 🚀 Thrilled to share that I’ve joined Harvard Medical School @harvardmed as an Asst. Professor and an Investigator at @BrighamWomens and the @MassGenBrigham Gene and Cell Therapy Institute! 🎉 The AbuGoot lab with @jgooten will work on programmable biology, novel gene/cell therapies, aging, and AI protein/cell design. Exciting times ahead! We are actively recruiting🌟 1/3
Omar Abudayyeh tweet media
English
29
45
406
48.6K
Jonathan Gootenberg
Jonathan Gootenberg@jgooten·
Genome editing has revolutionized the treatment of rare disease. What if we could put any change into RNA safely and reversibly? Today we (+ @omarabudayyeh ) debut PRECISE, allowing for RNA edits, deletions, and insertions from 1 to >1,000nt biorxiv.org/content/10.110… 🧵 1/x
Jonathan Gootenberg tweet media
English
9
84
378
48.2K
Jose Florez
Jose Florez@JoseFlorezMDPhD·
Excited to partner with my colleague @patrick_ellinor in co-leading this new alliance between @broadinstitute and @novonordisk in the cardiometabolic space. The goal is to use the power of human genomics and big data to identify disease-modifying drug targets.
Broad Institute@broadinstitute

Broad and @novonordisk are partnering on a new research alliance to identify therapeutic targets for type 2 diabetes and cardiometabolic diseases. The collaboration's goal is to improve standards of care for people living with both diseases. Learn more: broad.io/NovoNordisk-09…

English
5
9
88
15.4K
Shino Kany
Shino Kany@ShinoKany·
Very well earned, @patrick_ellinor! Couldn’t think of someone more deserving of this!
nancyatheart@NancyatHeart

Congrats to @American_Heart's 2023 Distinguished Scientists and Distinguished Scientist Lecturer. These scientific leaders making major independent contributions in CV, stroke and/or brain health research will be formally recognized during Scientific Sessions 2023 in Nov. (1/3)

English
3
4
20
3.1K
Brian Daniels retweetledi
Endpoints News
Endpoints News@endpts·
@JohnCendpts @rtnarch Nelsen shares that he was once asked about the secret to making deals. His response: "lack of knowledge...You have to have a sense to even be able to question the smartest people whether they’re right or wrong, and you have to have a tolerance for failure”
English
0
2
7
5.3K
Brian Daniels retweetledi
Michael Torres
Michael Torres@Mykalt45·
Pro tip: Translating academic research into drugs is hard. Doing it with a team that’s not equipped, hasn’t done it before, and led by people who “know enough to be dangerous” is a bad recipe. The funds and startups that address this fully will be better positioned to succeed.
English
1
3
33
0

Keşfet

@ARPA_H @MicrobiomDigest @manorlaboratory @AppleHelix @TesseraTx @gatesfoundation @RNAiAnalyst @yaireinhorn